Celebrating 10 years of Chromatin and Epigenetics

Our upcoming EMBL Conference: Chromatin and Epigenetics is celebrating its 10th anniversary this year! Although this year’s conference will be very different in format (yup, you guessed right: virtual!), the topics to be discussed will be as exciting as always.

We spoke to Asifa Akhtar and Geneviève Almouzni, the scientific organisers who have been there since the beginning of this conference series. Read on to find out what inspired them to organise this event in the first place, and what highlights can be expected at the virtual conference!

The Chromatin and Epigenetics conference is celebrating its 10th anniversary this year. How did it all start and how has it developed over the years?

GA: I was part of the original organisation committee when it started — 20 years ago already! A long journey already… The meeting actually started with the wish to give credit to my Postdoc mentor Dr. Alan Wolffe who had tragically passed away and was very active in the field. He was coined the “champion of Epigenetics” back then… You can see his picture in the corner of the conference image.

When I started my lab, he used to tease me about having a conference in Europe on a field that was just starting to take off. The fact is that since then it has become a major gathering of people in the field, including those actively engaged in the EC funded Network of Excellence — first the Epigenome and EpiGeneSys networks which expanded towards a broader community, including the LifeTime initiative and many friends from the 4DNucleome!  Undoubtedly, research over the past two decades has been incredibly active, leading to the deciphering of chromatin-based mechanisms, multi-scale genome organisation and the uncovering of the role of epigenetics in various human disorders with an increasing interest in studying the influence of age, environment, life style and disease states. I am really excited to hear about the latest news…

AA: I was part of the original organisation team, and being located at EMBL meant that I have been part of all the nitty gritty deals of organising this conference ever since. We have had a series of outstanding co-organisers on board, which also developed the breadth of the meeting over the last 20 years. We have kept up with the pace of the field, and this meeting is a major biennial scientific event in the chromatin and epigenetics field. The location at EMBL has been fantastic, with all the support and infrastructure available to run a big meeting like this. It continues to be a pleasure to organise this conference, and I am excited about all the possibilities that the virtual format will bring.

What inspired you to organise this conference?

GA: This meeting is dear to my heart, and it has surely brought together a wonderful community in Europe that is well linked with people worldwide. Also, from the inception we wanted to engage younger people in the organisation and serve the community. It has a unique spirit — it is collegial and friendly, and a place where new collaborations arise — and a growing network! The fact is that people always presented their most advanced work and unpublished data, thereby offering opportunities to discuss science in the making. We hope that the virtual conference version this year will retain this special touch.

AA: Alan Wolffe was a great chromatin biologist and his sudden passing took many of us by surprise, and left great sadness. He was a wonderful mentor and was interested in young scientists, a quality which I had always admired. Co-incidentally my husband was a postdoc in Alan’s lab, just like Genevieve. In fact, Alan’s plan was to visit him during his trip that eventually led to the tragedy. Co-organising the memorial workshop in his memory was an honour and in the long run a tremendously important decision, as this meeting became a focal point for chromatin biologists and epigeneticists to meet in Europe and share the wonders of the latest science we are all doing. The chromatin and epigenetics conference originated from initial event and has grown stronger over the years.

 Could you share what the focus and highlights of this year´s conference will be?

AA: The 10th conference in a series of meetings is a really memorable event and celebrating this during a global pandemic is a major challenge. We strive for excellence and this meeting will deliver many highlights and thrilling science. I very much hope that it will bring us together to appreciate the importance and perseverance of basic science, and that we celebrate coming together even in a virtual setting and show that we are dynamic and flexible, come what may…

GA: This year the session topics cover: Heterochromatin and HP1, developmental epigenetics, chromatin regulation, nucleosomes structure and function, transcription and chromatin defects and diseases, nuclear architecture as well as chromatin and RNA modifications. This is a very exciting program with both live-streamed invited speakers and selected short talks with Q&As, as well as digital poster sessions. We will also hold meet the speakers session along with some other surprises…

Among our speakers, Caroline Dean will tell us about cold-induced epigenetic switching in plants, Karen Adelman will discuss regulation of transcription elongation in development and diseases, Luciano di Croce the advances in the distinct role of Polycomb in stem biology and cancer, Bob Kingston on chromatin compaction and phase separation in epigenetic control of development, Danny Reinberg about Polycomb, inheritance and disease, Anja Groth will speak about chromatin replication and epigenome maintenance, Peter Becker will talk about how cooperation, competition and combination contribute to the targeting of the X chromosome and its regulation, Giacomo Cavalli and Allistair Boettiger about the 3D genome folding, Rick Young on Nuclear condensates, Tom Muir on chemical approaches and a Keynote by Wolf Reik on ways to exploit multiple single cell omics to unravel early embryo development.

Interested in this conference? Register by 19 April.

Follow us:

Meet the Trainers – Tobias Rausch and Alexey Larionov

On the occasion of World Cancer Day (4 February), we meet two of the trainers of the virtual EMBL Course: Cancer Genomics  (17 – 21 May 2021) – Tobias Rausch and Alexey Larionov.

PHOTO: EMBL Photolab

Tobias Rausch (TR) received his PhD in “Computational Biology and Scientific Computing” at the International Max Planck Research School in 2009. He then started to work at the European Molecular Biology Laboratory (EMBL) as a bioinformatician. His primary research interests are population and cancer genomics, structural variant discovery and omics computational methods development. (https://github.com/tobiasrausch).


PHOTO: Alexey Larionov

Initially educated as a clinical oncologist in Russia, Alexey Larionov (AL) switched to  experimental oncology upon completion of his PhD. Initially he worked as a postdoctoral researcher in Edinburgh University studying transcriptomics of breast cancer, with a focus on markers and mechanisms of endocrine response and resistance.  Working with data-rich methods (qPCR, micro-arrays, NGS) he became interested in data analysis and switched to bioinformatics. Since completing his MSc in Applied Bioinformatics, Alexey has worked as a bioinformatician at Cambridge University, focusing on NGS data analysis and heritable predisposition to cancer. See http://larionov.co.uk for more details.

What is your research focus?

TR: Computational genomics.

ALHeritable predisposition to cancer

Why did you choose to become a scientist?

TR: When I started at EMBL I saw myself as a software engineer who loves to design, develop and implement algorithms to solve data analysis problems. With the advent of high-throughput sequencing, this engineering background gave me a competitive edge as a data scientist, and that’s how it happened!

ALIt was interesting…

Where do you see this field heading in the future?

TR: Nowadays cancer genomics is a data-driven team science, but it is a long way from obtaining data to obtaining insight. In the age of analytics we all have to wrap our heads around multi-domain data with spatio-temporal resolution, ideally in real-time.

AL: I assume that the question is about translational cancer research in general.  I expect that in the near future the field needs better integration of different types of biological data and better collection of relevant clinical data. 

How has training influenced your career?

TR: I think training is essential to get you started. Training is like a kind person who takes your hand and guides you through unknown territory. It goes along with mentorship and I was lucky enough to have good training and good mentorship already as a student.

ALSince my initial clinical and bioinformatics degrees, cancer research has changed so much that I would not be able to even understand current papers if I hadn’t taken regular in-depth training in different aspects of computing and bioinformatics. 

How has cancer research changed over the years?

TR: I hope I am still too young to answer that :-). I leave that question for Bert Vogelstein or Robert A. Weinberg.

ALCancer research has become much more complex and powerful because of the development of new methods; specifically significant progress in bioinformatics, sequencing and human genomics.

Which methods and new technologies will be addressed in the course?

TR: We try to give an overview of how high-throughput sequencing can be applied in cancer genomics. We cover a range of technologies (short-read and long-read sequencing), data types (RNA-Seq, DNA-Seq and ATAC-Seq) and data modalities (bulk and single-cell sequencing), and last but not least – we take a deep dive into cancer genomics data analysis.

ALIn my sections of the course, I will discuss established methods for the analysis of bulk RNA sequencing, focusing on differential gene expression.  Then I will touch on the new methods being developed for the analysis of long-read RNA sequencing.  

What learning outcomes should participants expect to take home after the course?

TR: To come back to my previous answer: I hope after the course, cancer genomics won’t be an unknown territory anymore for the participants. I hope we pave the way and then it’s up to the students to make something out of it.

ALIn my section of the course, participants will learn:

1) Bioinformatics algorithms and tools for QC, alignment, and gene expression measurement in bulk short-read RNA-sequencing data

2) Current approaches to analysis of long-read RNA-seq data, comparing the Oxford Nanopore and PacBio sequencing technologies.

Interested in this course? Apply by 26 February.

For more upcoming events on cancer research take a look at our event listing.

Follow us:

CABANA – not just a shelter from the sun

You may have heard the name CABANA floating around the EMBL training programme, but you may not know exactly what it is. Here we present a handy guide to the project, its origins and where it stands now almost three years on from its launch.


CABANA is a capacity strengthening project for bioinformatics in Latin America. It aims to accelerate the implementation of data-driven biology in the region by creating a sustainable capacity-building programme focusing on three challenge areas – communicable disease, sustainable food production and protection of biodiversity.

Want to know more about the project? Check out this video from the CABANA consortium.

With just over a year left of the project, funded by the Global Challenges Research Fund (GCRF) – part of the UK Aid Budget, the capacity building element of the project is ramping up. A big part of the project is running a series of training events for the Latin American audience, something that began with the centralised events team within EMBL-EBI, but is now increasingly being operated in Latin America by the partners themselves.

CABANA has virtualised its training programme for the rest of 2020 and has committed to a fully virtual 2021 programme too. Check out the latest events on offer, or visit the new virtual training portal for the e-learning options.

Follow the CABANA project on Twitter or Facebook for the latest news and updates.

Follow us:

Ada Lovelace Day 2020 – The women of computational biology today

Ada Lovelace. Source: Suw Charman-Anderson on Flickr
Ada Lovelace as depicted by Suw Charman-Anderson on Flickr

Ada Lovelace is often regarded as the first to recognise the full potential of computers and as one of the first computer programmers. 

In honour of Ada Lovelace Day 2020we are shining the spotlight on some of the remarkable women that we have met during our training courses this year. 


Who? Hema Bye-A-Jee
Job title: Senior Scientific Database Curator, EMBL-EBI
Where to find her? Hema is delivering the webinar ‘A Guide to UniProt for Students’ via the EMBL-EBI training website tomorrow (14 October 2020). It is full, but the recording will be available the next day.

PHOTO: Hema Bye-A-Jee
PHOTO: Hema Bye-A-Jee

Tell us a bit about your work, what are you researching currently? 
I am a scientific curator for the UniProt team and I primarily sift through scientific publications to annotate C.elegans proteins, but I get to find out about lots of proteins in many organisms. Engaging with scientific and non-scientific communities is a very important aspect of what we do. Not only does my role feed my scientific curiosity, but it also enables me to help others to look at their data in different ways; we prepare specialised workshops and webinars, such as the “guide to UniProt for students” which I shall be presenting tomorrow.

What does it mean to you to be a woman in STEM today?
It means a lot because I know that many struggles and injustices have been endured, and it is unsettling that battles are still ongoing in many respects. I believe that science is for everyone and earning a place at the discovery table shouldn’t be based on gender, age, race, or even who shouts the loudest. If you can see beyond what’s right in front of you and can question it, surely you should at least be deserved of an invitation to be in the same room as the table!

What are your aspirations for your career in the future? 
I am very fortunate because I get to read about something new every day. I hope to continue working at the forefront of scientific discovery and innovation and take forwards my skills in communicating complex scientific principles, and wish to help others achieve the most from their data in the intellectual property law field.

Who? Rea Antoniou-Kourounioti
Job title: Postdoc at the John Innes Centre
Where to find her? Rea was a recent speaker at the EMBL-EBI Mathematics of Life: Modelling Molecular Mechanisms virtual course. You can find her slides on our ftp site.

Rea Antoniou-Kourounioti
Rea Antoniou-Kourounioti

Tell us a bit about your work, what are you researching currently?
My work combines mathematical modelling and experimental biology to understand how temperature affects when plants decide to flower. I am currently part of the groups of Martin Howard and Caroline Dean, and our work focuses on the gene FLC, which is epigenetically silenced in response to cold. We recently discovered one of the temperature sensing mechanisms that affect this gene and compared plants adapted to different climates. We found that the levels of the gene in autumn are very important for their different responses, and we are now trying to understand the mechanism that determines these levels.

Who or what inspired you to enter a career in STEM? 
I was fortunate to grow surrounded by academia, because both my parents were at the University, my mother specialising in biology and my father in maths. Therefore, I had many role models, though the pattern of women in biology/men in maths was prevalent in my environment. However, I was very close to a woman mathematician (the first female professor of Mathematics in Greece) who would give me puzzles to solve at all the grown-up parties. Solving puzzles was my passion then, and so it remains, and there are so many unsolved puzzles in biology!

What do you hope the future of working in STEM looks like?
More focus needs to be put towards understanding the complex reasons that women leave science at all career stages such as a different perception of worth, both from the outside and the inside. Hiring and assessment procedures favour characteristics associated with men, e.g., I still remember the lack of confidence I have had to battle to make my voice heard in meetings. This is deeply rooted in the differently promoted values for boys and girls and needs to be battled there and in its consequences. Events such as the Nobel prize recognising women this year helps girls to see that science is (also) for women and gives them inspiring role models like I was lucky to have.

Who? Zuzana Jandova
Job title: Postdoc at Utrecht University
Where to find her? Zuzana is a speaker at the upcoming BioExcel Winter School on Biomolecular Simulations event. Applications are currently open.

PHOTO: Zuzanna Jandova
PHOTO: Zuzanna Jandova

Tell us about your work, what are you working on right now?
As a part of the HADDOCK team at the Utrecht University, I focus on dissemination and training of our software as well as my own research. In training, we prepare tutorials, organise workshops and summer/winter schools, answer questions on public forums and make software easier and more approachable to users. In my own research, I look at how the combination of a traditional docking approach with molecular dynamics simulations and machine learning can improve the prediction of protein-protein interactions. This is then applied in areas like antibody design, where we can engineer antibodies in pharmaceutical research.

What are your aspirations for your career in the future?
I would like to stay in the biomedical field, where I also started when I decided to study pharmacy. Working in research, more specifically academia gave me a lot such as critical thinking, data management and project planning which I would like to take further into a more applied area. Thus, working in a pharmaceutical company or research institute where I could focus on not only the first theoretical stages of drug development but also on the further use of the drugs and biologics on the market would be a good option for me.

What does it mean to you to be a woman in STEM today?
To be honest I have never thought about my gender as a key element for my career choice. However, I realise that women are still somewhat underrepresented in computer or technical sciences in general. This is also why I think it is important that we talk more about women in science which can be a great example and inspiration for younger generations. And the more recognition we get, the more it becomes a norm to take women as an equal, respectable and knowledgeable part of the society. 

Name: Alessandra Villa
Job title: Senior Researcher at KTH Royal Institute of Technology
Where to find her? Alessandra is a speaker at the upcoming BioExcel Winter School on Biomolecular Simulations event. Applications are currently open.

PHOTO: Alessandra Villa
PHOTO: Alessandra Villa

Tell us about your work, what are you working on right now?
I was educated as a chemist. Early in my career, I realised that I was very interested in solving biophysical problems, thus I decided to do it using molecular modelling and computer simulation. My work focuses on improving molecular models to better describe how macromolecules interact. This can deepen our understanding of their function. Higher-education teaching has also played a key role in my career. Currently, I am working at the European Center of Excellence BioExcel, applying my expertise to promote and improve the use of advanced scientific tools.

What are your aspirations for your career in the future?
My aspiration is to contribute to building a lively environment that combines high-level teaching and research and to move to a coordination role with more decision power.  

What does it mean to you to be a woman in STEM today?
To be a scientist in STEM means to be able to understand, to contribute, to deepen our knowledge and to teach/disseminate on how nature (in my case molecules) function. In addition, it also means to be able to critically evaluate any new information and to be curious about things in general.  To be a woman in STEM is to be a scientist in STEM.

In the later stage of my career, I have realised that as a woman in STEM I always had to really demonstrate what I know. I was evaluated for what I did and not for what I could do, and further steps in my career may be full of “unpredictable” obstacles.

Name: Molly Gasperini
Job title: PhD Scientist, Octant
Where to find her? Molly was a speaker at a recent EMBL-EBI Industry Programme virtual workshop: High Throughput of Assessment of Functional Human Mutations. EMBL-EBI Industry programme members can download the slides from the members area.

PHOTO: Molly Gasperini
PHOTO: Molly Gasperini

Tell us a bit about your work, what are you researching currently?
I am developing high throughput functional assays to screen drugs against neuropsychiatric receptors at a scale and speed never before achieved. Find out more.

What does it mean to you to be a woman in STEM today?
I am extremely fortunate to be a part of science at a time where women generations before me (like Ada) have broken down many previous gender-based barriers. Though improvement is still required, most parts of science are largely welcoming for female scientists. Now, it is our responsibility to break down existing barriers for scientists who don’t identify with the racial, sexual-identity, or economic majority of the scientific community.

What are your aspirations for your career in the future?
I have always struggled with whether to climb the traditional ladder of leadership, though such job advancement takes you further from the bench and Rstudio, and into more meetings! Fundamentally, I hope to always continue working on thrilling tech dev as part of a rigorous and fun team.

Follow #ALD20 on Twitter to celebrate even more women, advocates and educators in STEM.


PHOTO: Michelle Mendonca
PHOTO: Michelle Mendonca

PHOTO: Rebecca Nicholl
PHOTO: Rebecca Nicholl

PHOTO: Emily Pomeroy
PHOTO: Emily Pomeroy
Follow us:

Meet the Trainers: Quantitative Proteomics Course


Meet Christina Ludwig (CL), Jeroen Krijgsveld (JK) and Mikhail Savitski (MS) – organisers of the virtual EMBO Practical Course: Quantitative Proteomics: Strategies and Tools to Probe Biology (3 – 7 May 2021). Since it first took place in 2016 it has grown in popularity and application numbers, reaching 164 applications for 24 seats in 2018. Christina, Jeroen and Mikhail share with us how the course has developed over the years and what their vision is for its future.

 1.  This year marks the 5th edition of the Quantitative Proteomics course. Back in 2016, why did you decide to organise it?

JK: The main motivation to initiate the course was because proteomics has become a mature technology that is increasingly being used by biologists to identify proteins, their modifications, interactions etc. However, few biologists have direct access to mass spectrometers, so they use them via collaborators or core facilities. They then get the results in a tabular form, often in a large excel sheet, from which they extract biological interpretation of the experiment. Importantly, we felt that the area between handing in a sample for mass spectrometric analysis and receiving the results was largely a black box. So in the course we aimed to demystify this, and explain the principles and strategies to generate information from raw MS data, and to train them in the use of computational tools to achieve this. Also, we aimed to give insight that proteomics can be done in various ways, so that participants may design their experiments such that they best address the question they are looking to answer. Finally, we aimed to equip participants with some terminology that will help them to communicate with their MS-collaborators, and ask the right questions. Because in many cases proteomics remains a team effort!

2. How has the course developed since?

JK: Proteomics is a very broad field with many mass spectrometric approaches, methods for data analysis and biological applications, making it impossible to cover this in a 1-week course. While in all editions of the course we have maintained a core that explains the main principles in proteomics and covers all of the current state-of-the-art quantitative technologies used in proteomics. Additionally, we have included other elements that varied over the years, to highlight emerging topics or specific application areas, e.g. in structural biology or immunology.

3. How do you choose which bioinformatics tools to cover in the course?

JK: There is an increasing number of bioinformatic tools that can analyse the same data using different underlying algorithms. Several of them have matured a lot over the years, making them more robust or have additional functionality. It is not always easy for anyone to know, when looking for an ‘analysis pipeline’, which tool can be best used. It can actually be a bit confusing that the same data can produce different results depending on the tool that is used, while at the same time none will be wrong. So instead of telling which tool is the best, we explain some of the underlying assumptions and the influence one has by choosing certain settings. I think for a researcher it is more important to justify how the data were processed, instead of saying that they used a certain software tool.

4. What could the techniques in this course be used for in the bigger picture?

CL: Proteomics technologies have reached a level of comprehensiveness, throughput and quantitative quality that was inconceivable just a few years back. However, applying proteomics to biological projects still requires lots of knowledge about experimental design, optimal sample preparation, most suitable mass spectrometric technologies and statistical interpretation. If we manage to bring both worlds together and teach biologists about the power, as well as the caveats, of proteomics, I think this will really impact life science in many aspects and truly transform the way how scientific projects are carried out for many scientists all over the world.

JK: I agree. Demonstrating the versatility, and thereby the potential and broad utility of proteomics in different contexts is sometimes an eye-opener for course participants. Actually, it is interesting and useful that participants come from all corners of biology, from paleobiology to clinical biomarker discovery. Having those together in a virtual room for a week and interact, with proteomics as the common interest, is fascinating to see as an organiser. And we explicitly facilitate such interactions in discussion groups – it is an important goal of the course.

5. How do you see this course growing in the future?

CL: I think one special feature of this course, compared to other proteomics courses, is that its rather familial in character due to the small number of 24 participants, and that they come from purposefully different countries and research institutes. This rather small group size is optimal in terms of group dynamics and allows lots of personal exchange between participants and speakers, as well as an optimal support during the practical sessions. Therefore, I hope also in the future the small and familiar atmosphere of this course will remain.

Due to the COVID-19 pandemic, this edition of the course will be 100% virtual. While we look forward to switching back a physical course format, we can definitely envision future courses with virtual components that entail those teaching-elements that work well in the virtual world, and are thereby easily accessible to a lot of people without traveling.

JK: What I also hope, and what we’ll try to achieve, is to remain up-to-date and include novel technologies that are emerging. After 20 years of steep development in mass spectrometry, one would expect that this levels off at some point, but this is not the case at all – it is actually difficult to keep up with what is happening, and with what is possible today that you would not dare to think about yesterday. Therefore, a remaining goal for us is to invite speakers and trainers who work at the forefront of technology, but who can also bridge this to important biological applications. This is what excites us as organisers, and we hope that this will help to make this one of the courses to go to for younger generations of scientists, and get infected too.

6. What motivates you most about your work?

CL: What I really love about heading a proteomics core facility is the huge variety of cool scientific projects you get exposed to, as well as the fact that you work closely with lots of very different scientists coming from completely different scientific disciplines. Every project and every collaboration partner challenges you in terms of diving into a new research area, providing an optimal proteomic workflow and also teaching and educating your collaboration partners in understanding their proteomic data.

MS: The fact that you have the constant possibility to come up and implement creative ideas is incredibly rewarding. Also the fact in research you are constantly generating results that are the first of their kind. There is always an experiment done that has not been done by anyone before and you are the first to see the results. I also love the academic environment the freedom and craziness of it all.

7. Why did you end up in the field of Proteins and Proteomics?

CL: Already during my Chemistry studies all the “biochemistry” lectures and practicals that focused on proteins and life sciences were by far the most interesting subjects for me. During my PhD, which I did in the field of protein engineering at the TU Dortmund, I studied a specific class of proteins, so called inteins, but I hardly applied any mass spectrometry during that time. However, for one specific experiment I used for the first time MALDI-MS to identify the reaction products of a set of purified inteins. My MALDI measurements showed the occurrences of an unexplainable loss of 18 m/z for one of my inteins. First I thought I did a mistake and was very frustrated. But when I repeated and further investigated my samples using also ESI tandem mass spectrometry I could proof the existence of a very interesting cyclic protein-intermediate, which actually helped me explaining the underlying protein splicing mechanism. This turned out being the most interesting result of my whole PhD.

MS: I originally was very focused on pure mathematics. By chance I had an encounter with Roman Zubarev who was a new professor at Uppsala University at the time. His drive, energy and passion for science convinced me to switch fields from mathematics to mass spectrometry and proteomics, which I never regretted.

8. What could you not do without in your life?

CL: Well, as a mother of two beautiful kids the very first thing I could not do without in my life is of course my family :)! And together with my family we love being outdoors, ideally in the Alps, either on (mountain)bikes, rock climbing or hiking. Living without mountains and outdoor activities would be very hard.

MS: First and foremost, my family! Second is physical activity. I love science and I love working a lot, but it takes its toll physically and mentally. My perfect way of recovering and getting the energy back is ideally by rock climbing, running and being out in nature in general.

9. If you would get the chance to meet a famous person – no matter if this person is still alive or not – who would that be?

CL: As a hobby climber I would really like to once meet Alex Honold, who is a world famous free-solo climber who climbed many of the most difficult and exposed climbs in Yosemite National Park without rope. Alex seems in interviews and videos like a really nice and funny guy, but I believe his brain must function very differently than mine when it comes to fear of height, so I would love chat with him about that ;).

MS: I was always interested in mathematics as well as computer science. It would have been fascinating to meet Alan Turing and discuss his vision of how things would develop based on what he knew back then. Incidentally, he was also a really excellent long distance runner with sub 3 hours’ marathon times. It would have been exciting to have a discussion over a run on the countryside :).

10. Which was the best decision in your career so far?

CL: I think the best decision for my career was to perform my Postdoc in the group of Professor Ruedi Abersold at the ETH Zürich, because this has really been the door opener for my career so far. When I finished my PhD it was actually not easy for me to decide for a postdoc in the field of mass spectrometry, because I hardly had any MS experience (I only performed this one MS experiment that I already described above ;)). And starting in a proteomics expert lab as a postdoc who had never really done proteomics before was definitely not easy in the beginning. But I did learn a lot of new things fast and ultimately this allowed me to bring together the two different expertises from my PhD and my Postdoc, which I do believe is a big advantage for any scientific career.

MS: Professionally, I think doing PhD in mass spectrometry was probably the best decision I have made so far. That early in your career, one still knows very little of the world and some luck is definitely required.

Interested in this course? Apply by 8 March!

Follow us: